D.E. Shaw & Co’s Outlook Therapeutics OTLK Stock Holding History

D.E. Shaw & Co’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-530	Closed	-$13K	–	5044
2022 Q3	$13K	Buy	+530	New	+$12.3K	﹤0.01%	4889
2021 Q3	–	Sell	-1,507	Closed	-$75K	–	5149
2021 Q2	$75K	Buy	+1,507	New	+$69.9K	﹤0.01%	4592

Other funds holding OTLK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

D.E. Shaw & Co's OTLK Position: Q4 2022 in Review

D.E. Shaw & Co sold out of Outlook Therapeutics (OTLK) in Q4 2022, closing a stake of 530 shares — an estimated $13K sold.

D.E. Shaw & Co first reported a position in OTLK in Q2 2021 and held it in 2 quarters. The position peaked at $75K in Q2 2021. 75 funds tracked by Wall St. Rank hold OTLK as of Q4 2022.

D.E. Shaw & Co reported no remaining Outlook Therapeutics position as of Q4 2022 after selling out during the quarter.
D.E. Shaw & Co sold 530 Outlook Therapeutics shares in Q4 2022, an estimated $13K.
D.E. Shaw & Co first reported a position in Outlook Therapeutics in Q2 2021 and held it in 2 quarters.
D.E. Shaw & Co's Outlook Therapeutics position peaked at $75K in Q2 2021.
75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.